IMMUNE MEDIATED THROMBOCYTOPENIA

Clinical trials for IMMUNE MEDIATED THROMBOCYTOPENIA explained in plain language.

Never miss a new study

Get alerted when new IMMUNE MEDIATED THROMBOCYTOPENIA trials appear

Sign up with your email to follow new studies for IMMUNE MEDIATED THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1 Terminated 1

Extended drug trial aims to keep transplant Patients' blood counts stable

Disease control Terminated

This was a follow-up study for people who had a stem cell transplant and then developed low blood cell counts (cytopenias). It aimed to see if taking the drug fostamatinib long-term (up to 21 more months) could safely help them maintain healthier levels of red blood cells or plat…

Matched conditions: IMMUNE MEDIATED THROMBOCYTOPENIA

Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

IMMUNE MEDIATED THROMBOCYTOPENIA

Get alerted when new IMMUNE MEDIATED THROMBOCYTOPENIA trials appear

Extended drug trial aims to keep transplant Patients' blood counts stable